Abstract

Background and aims: Timely access to approved medications is a priority in paediatric inflammatory bowel disease [IBD]. To date, the timing of drug studies in paediatric IBD has been suboptimal, with most studies conducted long after approval has been granted for adult IBD. This delay in approval leads to extensive off-label prescribing of medications in children, often without clear guidance on optimal dosing.

Tags

Clinical Trials, Colitis, Drug Approval, Drug Therapy, Inflammatory Bowel Diseases, Pediatrics

Read More